Upregulation of microRNA‑16 alters the response to inhaled β‑agonists in patients with asthma though modulating expression of ADRB2

Yu,Bo; Yao,Lusu; Liu,Cuiqiao; Tang,Lina; Xing,Tao

doi:10.3892/mmr.2019.10097

Upregulation of microRNA‑16 alters the response to inhaled β‑agonists in patients with asthma though modulating expression of ADRB2

Authors:
- Bo Yu
- Lusu Yao
- Cuiqiao Liu
- Lina Tang
- Tao Xing
View Affiliations

Affiliations: Department of Respiratory Medicine, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China, Department of Neurological Intensive Care Unit, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China
Published online on: March 28, 2019 https://doi.org/10.3892/mmr.2019.10097
Pages: 4027-4034
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are non‑coding RNAs of ~22 nucleotides in length, which serve an important role in numerous diseases. Asthma is a chronic airway inflammatory disease, which is the most common chronic disease among children. The role of miRNA (miR)‑16 in asthma is unclear. The objective of the present study was to examine the underlying molecular mechanism of the involvement of miR‑16 in asthma. A total of 72 volunteers diagnosed with asthma consented to participate in the study, of whom 52 participants were identified to be sensitive to salmeterol and 20 participants were identified to be resistant to salmeterol. Receiver operating characteristic (ROC) curve analysis was performed to compare the expression levels of serum miR‑16 between the sensitive and resistant groups, and to confirm the association between the expression level of serum miR‑16 and forced expiratory volume in 1 sec (FEV1). In silico analysis, a luciferase assay, reverse transcription‑quantitative polymerase chain reaction analysis and western blotting were performed to elucidate the molecular mechanism underlying the role of miR‑16 in asthma. ROC results demonstrated that the serum miR‑16 level may function as a biomarker to predict the response to salmeterol therapy, and the miR‑16 expression level displayed a significant negative correlation with FEV1. According to the in silico analysis, adrenoreceptor β‑2 (ADRB2) was a direct target of miR‑16, and it was further confirmed by luciferase assay that 25 nM miR‑16 mimic had an inhibitory effect on the luciferase activity of the wild‑type ADRB2 3' untranslated region (UTR); the inhibitory effect on the luciferase activity of the wild‑type ADRB2 3'UTR was stronger with 50 nM miR‑16 mimic, and strongest with 75 nM miR‑16 mimic, whereas the luciferase activity of the mutant ADRB2 3'UTR in cells was similar following treatment with 0, 25, 50 or 75 nM miR‑16 mimic. miR‑16 reduced the mRNA and protein expression levels of ADRB2 in a dose‑dependent manner. These results identified that miR‑16 may be used as a predictive biomarker of therapeutic response in asthma.

View Figures

View References

1	Burgess JA, Matheson MC, Gurrin LC, Byrnes GB, Adams KS, Wharton CL, Giles GG, Jenkins MA, Hopper JL, Abramson MJ, et al: Factors influencing asthma remission: A longitudinal study from childhood to middle age. Thorax. 66:508–513. 2011. View Article : Google Scholar : PubMed/NCBI
2	Pavord ID: Non-eosinophilic asthma and the innate immune response. Thorax. 62:193–194. 2007. View Article : Google Scholar : PubMed/NCBI
3	Donohue JF, Herje N, Crater G and Rickard K: Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: A pilot study. Int J Chron Obstruct Pulmon Dis. 9:745–751. 2014. View Article : Google Scholar : PubMed/NCBI
4	Leung DY and Bloom JW: Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 111:3–22; quiz 23. 2003. View Article : Google Scholar : PubMed/NCBI
5	Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Piñeiro A, Wei LX, Seidenberg BC and Reiss TF: Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med. 130:487–495. 1999. View Article : Google Scholar : PubMed/NCBI
6	Leung DY, Martin RJ, Szefler SJ, Sher ER, Ying S, Kay AB and Hamid Q: Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med. 181:33–40. 1995. View Article : Google Scholar : PubMed/NCBI
7	Drazen JM: Asthma: The paradox of heterogeneity. J Allergy Clin Immunol. 129:1200–1201. 2012. View Article : Google Scholar : PubMed/NCBI
8	Yang M, Kumar RK, Hansbro PM and Foster PS: Emerging roles of pulmonary macrophages in driving the development of severe asthma. J Leukoc Biol. 91:557–569. 2012. View Article : Google Scholar : PubMed/NCBI
9	Kunos G and Szentivanyi M: Evidence favouring the existence of a single adrenergic receptor. Nature. 217:1077–1078. 1968. View Article : Google Scholar : PubMed/NCBI
10	Shelhamer JH, Marom Z and Kaliner M: Abnormal beta-adrenergic responsiveness in allergic subjects. II. The role of selective beta 2-adrenergic hyporeactivity. J Allergy Clin Immunol. 71:57–61. 1983. View Article : Google Scholar : PubMed/NCBI
11	Marsh DG, Neely JD, Breazeale DR, Ghosh B, Freidhoff LR, Ehrlich-Kautzky E, Schou C, Krishnaswamy G and Beaty TH: Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science. 264:1152–1156. 1994. View Article : Google Scholar : PubMed/NCBI
12	Postma DS, Bleecker ER, Amelung PJ, Holroyd KJ, Xu J, Panhuysen CI, Meyers DA and Levitt RC: Genetic susceptibility to asthma-bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med. 333:894–900. 1995. View Article : Google Scholar : PubMed/NCBI
13	Inui M, Martello G and Piccolo S: MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 11:252–263. 2010. View Article : Google Scholar : PubMed/NCBI
14	Chen CZ, Li L, Lodish HF and Bartel DP: MicroRNAs modulate hematopoietic lineage differentiation. Science. 303:83–86. 2004. View Article : Google Scholar : PubMed/NCBI
15	Ariel D and Upadhyay D: The role and regulation of microRNAs in asthma. Curr Opin Allergy Clin Immunol. 12:49–52. 2012. View Article : Google Scholar : PubMed/NCBI
16	Jardim MJ, Dailey L, Silbajoris R and Diaz-Sanchez D: Distinct microRNA expression in human airway cells of asthmatic donors identifies a novel asthma-associated gene. Am J Respir Cell Mol Biol. 47:536–542. 2012. View Article : Google Scholar : PubMed/NCBI
17	Solberg OD, Ostrin EJ, Love MI, Peng JC, Bhakta NR, Hou L, Nguyen C, Solon M, Nguyen C, Barczak AJ, et al: Airway epithelial miRNA expression is altered in asthma. Am J Respir Crit Care Med. 186:965–974. 2012. View Article : Google Scholar : PubMed/NCBI
18	Burger H, van Leen RW, Dorssers LC, Persoon NL, Lemson PJ and Wagemaker G: Species specificity of human interleukin-3 demonstrated by cloning and expression of the homologous rhesus monkey (Macaca mulatta) gene. Blood. 76:2229–2234. 1990.PubMed/NCBI
19	Zhang YY, Zhong M, Zhang MY and Lv K: Expression and clinical significance of miR-155 in peripheral blood CD4(+); T cells of patients with allergic asthma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 28:540–543. 2012.(In Chinese). PubMed/NCBI
20	Panganiban RP, Wang Y, Howrylak J, Chinchilli VM, Craig TJ, August A and Ishmael FT: Circulating microRNAs as biomarkers in patients with allergic rhinitis and asthma. J Allergy Clin Immunol. 137:1423–1432. 2016. View Article : Google Scholar : PubMed/NCBI
21	Gimenez LE, Baameur F, Vayttaden SJ and Clark RB: Salmeterol efficacy and bias in the activation and kinase-mediated desensitization of β2-adrenergic receptors. Mol Pharmacol. 87:954–964. 2015. View Article : Google Scholar : PubMed/NCBI
22	Berger WE and Noonan MJ: Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): An inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler. J Asthma. 47:447–459. 2010. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2011. View Article : Google Scholar
24	Kuhn RM, Haussler D and Kent WJ: The UCSC genome browser and associated tools. Brief Bioinform. 14:144–161. 2013. View Article : Google Scholar : PubMed/NCBI
25	Perry MM, Moschos SA, Williams AE, Shepherd NJ, Larner-Svensson HM and Lindsay MA: Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells. J Immunol. 180:5689–5698. 2008. View Article : Google Scholar : PubMed/NCBI
26	Mi S, Zhang J, Zhang W and Huang RS: Circulating microRNAs as biomarkers for inflammatory diseases. Microrna. 2:63–71. 2013. View Article : Google Scholar : PubMed/NCBI
27	Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, et al: A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 129:1401–1414. 2007. View Article : Google Scholar : PubMed/NCBI
28	Lerner M, Harada M, Lovén J, Castro J, Davis Z, Oscier D, Henriksson M, Sangfelt O, Grandér D and Corcoran MM: DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res. 315:2941–2952. 2009. View Article : Google Scholar : PubMed/NCBI
29	Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C, et al: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 14:1271–1277. 2008. View Article : Google Scholar : PubMed/NCBI
30	Wang F, Fu XD, Zhou Y and Zhang Y: Down-regulation of the cyclin E1 oncogene expression by microRNA-16-1 induces cell cycle arrest in human cancer cells. BMB Rep. 42:725–730. 2009. View Article : Google Scholar : PubMed/NCBI
31	Chung EY, Dews M, Cozma D, Yu D, Wentzel EA, Chang TC, Schelter JM, Cleary MA, Mendell JT and Thomas-Tikhonenko A: c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster. Cancer Biol Ther. 7:1758–1764. 2008. View Article : Google Scholar : PubMed/NCBI
32	Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 99:15524–15529. 2012. View Article : Google Scholar
33	Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, Chen H and Lu X: Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res. 70:7176–7186. 2010. View Article : Google Scholar : PubMed/NCBI
34	Kim WJ, Oh YM, Sung J, Kim TH, Huh JW, Jung H, Lee JH, Kim EK, Lee JH, Lee SM, et al: Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung. 186:381–386. 2008. View Article : Google Scholar : PubMed/NCBI
35	Litonjua AA, Gong L, Duan QL, Shin J, Moore MJ, Weiss ST, Johnson JA, Klein TE and Altman RB: Very important pharmacogene summary ADRB2. Pharmacogenet Genomics. 20:64–69. 2010. View Article : Google Scholar : PubMed/NCBI
36	Pignatti PF: Trends in pharmacogenomics of drugs used in the treatment of asthma. Pharmacol Res. 49:343–349. 2004. View Article : Google Scholar : PubMed/NCBI
37	Brodde OE and Leineweber K: Beta2-adrenoceptor gene polymorphisms. Pharmacogenet Genomics. 15:267–275. 2005. View Article : Google Scholar : PubMed/NCBI
38	Contopoulos-Ioannidis DG, Manoli EN and Ioannidis JP: Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. J Allergy Clin Immunol. 115:963–972. 2005. View Article : Google Scholar : PubMed/NCBI
39	Ortega VE, Hawkins GA, Moore WC, Hastie AT, Ampleford EJ, Busse WW, Castro M, Chardon D, Erzurum SC, Israel E, et al: Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: A genetic study. Lancet Respir Med. 2:204–213. 2014. View Article : Google Scholar : PubMed/NCBI
40	Hawkins GA, Tantisira K, Meyers DA, Ampleford EJ, Moore WC, Klanderman B, Liggett SB, Peters SP, Weiss ST and Bleecker ER: Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med. 174:1101–1109. 2006. View Article : Google Scholar : PubMed/NCBI
41	Green SA, Turki J, Innis M and Liggett SB: Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 33:9414–9419. 1994. View Article : Google Scholar : PubMed/NCBI
42	Green SA, Cole G, Jacinto M, Innis M and Liggett SB: A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem. 268:23116–23121. 1993.PubMed/NCBI
43	Barbato E, Penicka M, Delrue L, Van Durme F, De Bruyne B, Goethals M, Wijns W, Vanderheyden M and Bartunek J: Thr164Ile polymorphism of beta2-adrenergic receptor negatively modulates cardiac contractility: Implications for prognosis in patients with idiopathic dilated cardiomyopathy. Heart. 93:856–861. 2007. View Article : Google Scholar : PubMed/NCBI
44	Davis JS, Sun M, Kho AT, Moore KG, Sylvia JM, Weiss ST, Lu Q and Tantisira KG: Circulating microRNAs and association with methacholine PC20 in the Childhood Asthma Management Program (CAMP) cohort. PLoS One. 12:e01803292017. View Article : Google Scholar : PubMed/NCBI